Global Diabetic Macular Edema Treatment Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Diabetic Macular Edema Treatment Market Research Report 2024
Diabetic macular edema (DME) is characterized by accumulation of fluid in the macula – a part of retina responsible for vision. Accumulation may cause by leakage of plasma constituents into the surrounding, consequently leading to edema.
According to MRAResearch’s new survey, global Diabetic Macular Edema Treatment market is projected to reach US$ 3327.9 million in 2033, increasing from US$ 2954.8 million in 2022, with the CAGR of 2.1% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Diabetic Macular Edema Treatment market research.
Increasing prevalence of diabetes in the prime factor driving growth of global diabetic macular edema therapeutics market. The prevalence of diabetic macular edema is higher in type 2 diabetes patients than in type 1 diabetes patients. As per study conducted by University Hospital Sant Joan de Reus Spain, the incidence of diabetic macular edema is in the range of 0.9%-2.3%, annually, across the globe. Besides this, substantial R&D investment by pharmaceutical companies and advancement in ophthalmic surgrey techniques are some other factors fueling the growth of global diabetic macular edema treatment market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Diabetic Macular Edema Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Genentech
Novartis
GlaxoSmithKline
Eyetech Pharmaceuticals
Alimera Sciences
Segment by Type
Laser Photocoagulation Therapy
Pharmacological Therapy
Bevacizumab
Ranibizumab
Triamcinolone
Hospitals
Ophthalmic Clinics
Research Institutes
Contract Research Organizations
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Diabetic Macular Edema Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Diabetic Macular Edema Treatment market is projected to reach US$ 3327.9 million in 2033, increasing from US$ 2954.8 million in 2022, with the CAGR of 2.1% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Diabetic Macular Edema Treatment market research.
Increasing prevalence of diabetes in the prime factor driving growth of global diabetic macular edema therapeutics market. The prevalence of diabetic macular edema is higher in type 2 diabetes patients than in type 1 diabetes patients. As per study conducted by University Hospital Sant Joan de Reus Spain, the incidence of diabetic macular edema is in the range of 0.9%-2.3%, annually, across the globe. Besides this, substantial R&D investment by pharmaceutical companies and advancement in ophthalmic surgrey techniques are some other factors fueling the growth of global diabetic macular edema treatment market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Diabetic Macular Edema Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
Genentech
Novartis
GlaxoSmithKline
Eyetech Pharmaceuticals
Alimera Sciences
Segment by Type
Laser Photocoagulation Therapy
Pharmacological Therapy
Bevacizumab
Ranibizumab
Triamcinolone
Segment by Application
Hospitals
Ophthalmic Clinics
Research Institutes
Contract Research Organizations
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Diabetic Macular Edema Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
